Phospholipid-metabolizing enzymes in Alzheimer's disease: Increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity

Journal of Neurochemistry

Volumn 70, Issue 2, 1998, Pages 786-793

  Ross, Brian M ^a,b   Moszczynska, Anna ^a   Erlich, Jeffrey ^a   Kish, Stephen J ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Choline kinase; Choline phosphotransferase; Glycerophosphocholine; Lysophospholipid acyltransferase; Phosphocholine cytidylyltransferase; Phosphodiesterase; Phospholipase A2

Indexed keywords

ACYLTRANSFERASE; CHOLINE KINASE; CHOLINEPHOSPHOTRANSFERASE; ETHANOLAMINE KINASE; ETHANOLAMINE PHOSPHOTRANSFERASE; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPID;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN BIOPSY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE DEGENERATION; PATHOPHYSIOLOGY; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL;

EID: 0031937355     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70020786.x     Document Type: Article

References (44)

1. Alberghina M., Lupo G., Anfuso C., and el Ghonemy S. H. I. (1995) Lipid peroxidation inhibits acyl-CoA:1-acyl-sn-glycero-3-phosphocholine O-acyltransferase but not CTP:phosphocholine cytidylyltransferase activity in rat brain membranes. Neurochem. Int. 26, 477-487.
2. Anfuso C. D., Lupo G., Sipione S., and Alberghina M. (1994) Susceptibility of rat retina acyl-CoA:1-acyl-sn-glycero-3-phosphocholine O-acyltransferase and CTP:phosphocholine cytidylyltransferase activity to lipid peroxidation and hydroperoxide treatment. FEBS Lett. 347, 123-127.
3. 2. Biosci. Biotechnol. Biochem. 57, 2200-2201.
4. Bergeron C. and Pollanen M. (1989) Lewy bodies in Alzheimer's disease - one or two diseases? Alzheimer Dis. Assoc. Disord. 4, 197-204.
5. Blusztajn J. K., Gonzalez-Coviella I., Logue M., Growdon J. H., and Wurtman R. J. (1990) Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients. Brain Res. 536, 240-244.
6. Brooksbank B. W. L. and Martinez M. (1989) Lipid abnormalities in the brain of adult Down's syndrome and Alzheimer's disease. Mol. Chem. Neuropathol. 12, 157-185.
7. Cacabelos R., Caamano J., Gomez M. J., Fernandez-Novoa L., Franco-Maside A., and Alvarez X. A. (1996) Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular dynamics, and immune factors. Ann. NY Acad. Sci. 777, 399-403.
8. Cornell R. B. (1992) Choline phosphotransferase from mammalian sources. Methods Enzymol. 209, 267-272.
9. Cuenod C. A., Kaplan D. B., Michot J. L., Jehenson P., Leroy-Willig A., Forette F., Syrota A., and Boller F. (1995) Phospholipid abnormalities in early Alzheimer's disease. Arch. Neurol. 52, 89-94.
10. Ellison D. W., Beal M. F., and Martin J. B. (1987) Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Res. 417, 389-392.
11. Emmerling M. R., Dudley D. T., Dyer R. D., Carrol R. T., Doyle P. D., and Davis R. E. (1996) The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). Ann. NY Acad. Sci. 777, 310-315.
12. Farooqui A. A., Wells K., and Horrocks L. A. (1995) Breakdown of membrane phospholipids in Alzheimer's disease. Involvement of excitatory amino acid receptors. Mol. Chem. Neuropathol. 25, 155-173.
13. 2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 246, 129-131.
14. Ginsberg L., Rafique S., Xuereb J. H., Rapoport S. I., and Gershfeld N. L. (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 698, 223-226.
15. 2 from bovine brain cytosol. J. Neurochem. 59, 708-714.
16. Kanfer J. N., Hattori H., and Orihel D. (1986) Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients. Ann. Neurol. 20, 265-267.
17. Kanfer J. N., Pettegrew J. W., Moossy J., and McCartney D. G. (1993) Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls. Neurochem. Res. 18, 331-334.
18. Kanfer J. N., Singh I. N., Pettegrew J. W., McCartney D. G., and Sorrentino G. (1996) Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. J. Lipid Mediat. Cell Signal. 14, 361-363.
19. Kienzl E., Puchinger L., Jellinger K., Stachelberger H., and Varmuza K. (1993) Studies of phospholipid composition in Alzheimer's disease brain. Neurodegeneration 2, 101-109.
20. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 17, 349-357.
21. Kwon E. D., Jung K. J., Edsall L. C., Kim H. Y., Garcia-Perez A., and Burg M. (1995) Osmotic regulation of synthesis of glycerophosphocholine from phosphatidylcholine in MDCK cells. Am. J. Physiol. 268, C402-C414.
22. 2 by amyloid beta-peptides in vitro. Biochemistry 35, 9407-9414.
23. López-Coviella I., Agut J., Savci V., Ortiz J. A., and Wurtman R. J. (1995) Evidence that 5′-cytidinephosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J. Neurochem. 65, 889-894.
24. Mastrogiacomo F., Bergeron C., and Kish S. J. (1993) Brain α-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J. Neurochem. 61, 2007-2014.
25. 2(s); comparison of arachidonyl-selective and -nonselective enzymes. FASEB J. 7, 339-348.
26. Morrison L. D., Smith D. D., and Kish S. J. (1996) Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem. 67, 1328-1331.
27. Nitsch R. M., Blusztajn J. K., Pittas A. G., Slack B., Growdon J. H., and Wurtman R. J. (1992) Evidence for a membrane defect in Alzheimer's disease brain. Proc. Natl. Acad. Sci. USA 89, 1671-1675.
28. Olanow C. W. (1993) A radical hypothesis for neurodegeneration. Trends Neurosci. 16, 439-444.
29. Orr H. T., Chung M., Banfi S., Kwiatkowski T. J., Servadio A., Beaudet A. L., McCall A. E., Duvick L. A., Ranum L. P. W., and Zogbhi H. Y. (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 4, 221-226.
30. Perry R. H., Perry E. K., Smith C. J., Xuereb J. H., Irving D., Whitford C. A., Candy J. M., and Cross A. J. (1987) Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. J. Neural Transm. Suppl. 24, 131-136.
31. Pettegrew J. W., Panchalingam K., Moossy J., Martinez J., Rao G., and Boller F. (1988) Correlation of phosphorous-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch. Neurol. 45, 1093-1096.
32. Pettegrew J. W., Klunk W. E., Kanal E., Panchalingam K., and McClure R. J. (1995) Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging 6, 973-975.
33. Robitaille Y., Schut L., and Kish S. J. (1995) Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the SCA-1 mutation define a unique phenotype. Acta Neuropathol (Berl.) 90, 572-581.
34. 2 activity in gerbil brain: enhanced activities of cytosolic, mitochondrial and microsomal forms after ischemia and reperfusion. J. Neurosci. 11, 1829-1836.
35. Ross B. M. and Kish S. J. (1994) Characterization of lysosphospholipid metabolizing enzymes in human brain. J. Neurochem. 63, 1839-1848.
36. 2 activity in human brain. J. Neurochem. 64, 2213-2221.
37. Ross B. M., Sherwin A. L., and Kish S. J. (1995b) Multiple forms of the enzyme glycerophosphodiesterase are present in human brain. Lipids 30, 1075-1081.
38. 2 activity is selectively decreased in the striatum of chronic cocaine users. J. Neurochem. 67, 2620-2623.
39. Ross B. M., Moszczynska A., Blusztajn J. K., Sherwin A., and Kish S. J. (1997) Phospholipid biosynthetic enzymes in human brain Lipids 32, 351-358.
40. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiol. Aging 14, 85-92.
41. Stokes C. E. and Hawthorne J. N. (1987) Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J. Neurochem. 48, 1018-1021.
42. Teegarden D. E., Taparowsky E., and Kent C. (1990) Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with with the Harvey-ras oncogene. J. Biol. Chem. 265, 6042-6047.
43. 2: a monolayer study. Biochemistry 32, 4962-4967.
44. Wells K., Farooqui A. A., Liss L., and Horrocks L. (1995) Neural membrane phospholipids in Alzheimer's disease. Neurochem. Res. 20, 1329-1333.